UCB has presented the first pooled data analysis from phase 3 trials of its bimekizumab treatment for moderate to severe hidradenitis suppurativa at the European Academy of Dermatology and Venereology (EADV) Congress. The analysis showed the treatment led to clinically important improvements and a large percentage of patients who achieved a high skin response after 16 weeks maintained their response up to 48 weeks.

DeepSeek iOS app sends data unencrypted to ByteDance-controlled servers
DeepSeek, an app by ByteDance, sends data, including encrypted information, to servers located in China, leading to concerns over privacy breaches. After security firm Wiz